Supriya Lifescience Limited (SUPRIYA) - Net Assets
Based on the latest financial reports, Supriya Lifescience Limited (SUPRIYA) has net assets worth Rs10.82 Billion INR (≈ $116.99 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs12.03 Billion ≈ $130.10 Million USD) and total liabilities (Rs1.21 Billion ≈ $13.10 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Supriya Lifescience Limited's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs10.82 Billion |
| % of Total Assets | 89.93% |
| Annual Growth Rate | 51.4% |
| 5-Year Change | 270.62% |
| 10-Year Change | N/A |
| Growth Volatility | 39.01 |
Supriya Lifescience Limited - Net Assets Trend (2018–2025)
This chart illustrates how Supriya Lifescience Limited's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Supriya Lifescience Limited for the complete picture of this company's asset base.
Annual Net Assets for Supriya Lifescience Limited (2018–2025)
The table below shows the annual net assets of Supriya Lifescience Limited from 2018 to 2025. For live valuation and market cap data, see SUPRIYA company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs9.97 Billion ≈ $107.80 Million |
+22.25% |
| 2024-03-31 | Rs8.15 Billion ≈ $88.18 Million |
+16.57% |
| 2023-03-31 | Rs6.99 Billion ≈ $75.64 Million |
+13.61% |
| 2022-03-31 | Rs6.16 Billion ≈ $66.58 Million |
+128.93% |
| 2021-03-31 | Rs2.69 Billion ≈ $29.08 Million |
+80.26% |
| 2020-03-31 | Rs1.49 Billion ≈ $16.13 Million |
+59.07% |
| 2019-03-31 | Rs937.91 Million ≈ $10.14 Million |
+71.60% |
| 2018-03-31 | Rs546.57 Million ≈ $5.91 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Supriya Lifescience Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1853.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs7.82 Billion | 78.45% |
| Common Stock | Rs160.97 Million | 1.61% |
| Other Comprehensive Income | Rs1.57 Million | 0.02% |
| Other Components | Rs1.99 Billion | 19.92% |
| Total Equity | Rs9.97 Billion | 100.00% |
Supriya Lifescience Limited Competitors by Market Cap
The table below lists competitors of Supriya Lifescience Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PWR Holdings Ltd
AU:PWH
|
$604.88 Million |
|
Jiangxi Huawu Brake Co Ltd
SHE:300095
|
$604.89 Million |
|
Tipco Asphalt Public Company Limited
F:NVP5
|
$605.25 Million |
|
Poly Union Chemical Holding Group Co Ltd
SHE:002037
|
$605.40 Million |
|
Biglari Holdings Inc
NYSE:BH
|
$604.53 Million |
|
Northpointe Bancshares, Inc.
NYSE:NPB
|
$604.47 Million |
|
Hamaton Automotive Technology Co Ltd
SHE:300643
|
$604.04 Million |
|
Sun International Ltd
JSE:SUI
|
$603.88 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Supriya Lifescience Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,153,660,000 to 9,967,600,000, a change of 1,813,940,000 (22.2%).
- Net income of 1,879,580,000 contributed positively to equity growth.
- Dividend payments of 64,390,000 reduced retained earnings.
- Other comprehensive income decreased equity by 1,243,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs1.88 Billion | +18.86% |
| Dividends Paid | Rs64.39 Million | -0.65% |
| Other Comprehensive Income | Rs-1.24 Million | -0.01% |
| Other Changes | Rs-7.00K | -0.0% |
| Total Change | Rs- | 22.25% |
Book Value vs Market Value Analysis
This analysis compares Supriya Lifescience Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.61x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 93.04x to 5.61x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-03-31 | Rs7.47 | Rs694.90 | x |
| 2019-03-31 | Rs36.71 | Rs694.90 | x |
| 2020-03-31 | Rs58.40 | Rs694.90 | x |
| 2021-03-31 | Rs105.27 | Rs694.90 | x |
| 2022-03-31 | Rs76.50 | Rs694.90 | x |
| 2023-03-31 | Rs86.91 | Rs694.90 | x |
| 2024-03-31 | Rs101.31 | Rs694.90 | x |
| 2025-03-31 | Rs123.83 | Rs694.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Supriya Lifescience Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.86%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 26.99%
- • Asset Turnover: 0.63x
- • Equity Multiplier: 1.12x
- Recent ROE (18.86%) is below the historical average (28.02%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 15.97% | 4.10% | 0.87x | 4.49x | Rs32.62 Million |
| 2019 | 42.03% | 14.19% | 1.10x | 2.70x | Rs300.45 Million |
| 2020 | 49.20% | 23.55% | 0.93x | 2.25x | Rs584.84 Million |
| 2021 | 45.96% | 32.07% | 0.86x | 1.66x | Rs966.99 Million |
| 2022 | 24.66% | 29.23% | 0.71x | 1.19x | Rs902.41 Million |
| 2023 | 12.85% | 19.92% | 0.55x | 1.17x | Rs199.11 Million |
| 2024 | 14.61% | 20.88% | 0.62x | 1.13x | Rs375.77 Million |
| 2025 | 18.86% | 26.99% | 0.63x | 1.12x | Rs882.82 Million |
Industry Comparison
This section compares Supriya Lifescience Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $9,744,868,500
- Average return on equity (ROE) among peers: 4.50%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Supriya Lifescience Limited (SUPRIYA) | Rs10.82 Billion | 15.97% | 0.11x | $604.83 Million |
| BALAXI PHARMACEUTICALS LIMITED (BALAXI) | $2.01 Billion | -1.19% | 0.28x | $15.90 Million |
| Blue Jet Healthcare Limited (BLUEJET) | $6.81 Billion | 23.48% | 0.26x | $833.96 Million |
| Concord Biotech Limited (CONCORDBIO) | $11.03 Billion | 15.86% | 0.19x | $1.29 Billion |
| Dishman Carbogen Amcis Limited (DCAL) | $55.49 Billion | 0.32% | 0.56x | $310.59 Million |
| Lyka Labs Limited (LYKALABS) | $-151.11 Million | 0.00% | 0.00x | $23.04 Million |
| SMS Lifesciences India Limited (SMSLIFE) | $1.94 Billion | 4.70% | 1.02x | $42.13 Million |
| Take Solutions Limited (TAKE) | $20.00 Million | 0.00% | 0.50x | $67.51 Million |
| Zota Health Care LImited (ZOTA) | $803.57 Million | -7.18% | 0.97x | $430.12 Million |
About Supriya Lifescience Limited
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti"hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary… Read more